We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.01 | 0.11% | 9.05 | 39,733 | 16:35:19 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.00 | 9.10 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.37 | 52.78M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:59:17 | O | 20,000 | 9.0048 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/11/2023 | 14:34 | ALNC |  EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production |
| 02/11/2023 | 07:00 | UKREG | e-Therapeutics plc Strategic RWE collaboration with Arcturis |
| 26/10/2023 | 17:12 | ALNC | EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half |
| 26/10/2023 | 06:38 | UKREG | e-Therapeutics plc Interim results for the six months to 31 July 2023 |
| 19/10/2023 | 08:54 | UKREG | e-Therapeutics plc Notice of Interim Results |
| 29/9/2023 | 15:30 | UKREG | e-Therapeutics plc Total Voting Rights |
| 20/9/2023 | 13:37 | ALNC | TRADING UPDATES: Capital inks contract; Lansdowne becomes cash shell |
| 20/9/2023 | 06:00 | UKREG | e-Therapeutics plc Senior Management Update |
| 07/9/2023 | 10:47 | UKREG | e-Therapeutics plc Exercise of Options and Issue of Equity |
| 31/7/2023 | 15:30 | UKREG | e-Therapeutics plc Total Voting Rights |
E-therapeutics (ETX) Share Charts1 Year E-therapeutics Chart |
|
1 Month E-therapeutics Chart |
Intraday E-therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/11/2023 | 07:35 | E-Therapeutics ETX : Applying AI / ML to drug discovery & development | 957 |
| 13/9/2020 | 13:39 | ETX : Stocktube Vid | 75 |
| 13/9/2020 | 13:39 | ETX, The Boss & the Company | 3 |
| 13/9/2020 | 13:39 | ETX-Fighting MRSA & winning. | 1,095 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-12-06 15:59:18 | 9.00 | 20,000 | 1,800.96 | O |
| 2023-12-06 13:28:16 | 9.23 | 10,853 | 1,001.98 | O |
| 2023-12-06 08:17:50 | 9.01 | 8,880 | 800.09 | O |
| Top Posts |
|---|
Posted at 06/12/2023 08:20 by E-therapeutics Daily Update E-therapeutics Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ETX. The last closing price for E-therapeutics was 9.04p.E-therapeutics currently has 583,844,162 shares in issue. The market capitalisation of E-therapeutics is £52,779,512. E-therapeutics has a price to earnings ratio (PE ratio) of -6.37. This morning ETX shares opened at - |
Posted at 28/9/2023 14:00 by 1347 What'a this got to do with ETX? |
Posted at 25/9/2023 12:42 by maccamcd Did you listen in on the investor meet presentation a few months ago?I believe it's been mainly one retail investor who's been selling bits continuously...Annoy |
Posted at 25/9/2023 12:06 by 1347 Do ETX do anything, or have they become just another placings today, jam tomorrow company? I hope it's not going the same way as DeepMatter, it was a disgrace what happened there and I note Griff is involved in both. Ali needs to get his finger out and let shareholders know what they are doing, if anything. |
Posted at 13/7/2023 10:01 by maccamcd Have you all seen this news???Recursion Pharmaceuticals (RXRX.NQ) strikes computational drug discovery deal with Nvidia (NVDA.NQ). • Recursion Pharmaceuticals, an AI drug discovery business, announced a collaboration and $50m equity investment by Nvidia. • Under the agreement, the partners aim to use Recursion’s biological and chemical datasets to accelerate the training of computational models on Nvidia’s platform. • These models could be used for commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. • Recursion also expects to use this software to support its internal pipeline and its current and future partners. The agreement demonstrates the continued interest of generative AI in drug discovery. BioNeMo incorporates large language models (LLMs) into its platform. LLMs, such as Chat GPT-4, are a type of AI trained on large datasets to perform a wide range of tasks, such as generating new hypotheses, predicting protein-protein interactions as well as analysing biomedical literature and patent information at scale. Although LLMs show promise in improving drug discovery activities, few companies have integrated this technology into their operations. The slow adoption of LLMs in the pharmaceutical industry leaves a significant opportunity for first movers to capture interest in this area. On AIM, ETX is integrating Large Language Models (LLMs) into its own platform. |
Posted at 03/7/2023 09:28 by maccamcd this Companymeet presentation should be informative! Hopefully Ali gives colour on the speed of larger biotech jv interest. At the moment it's hard to quantify what this AI boom really means for ETX in $You all registered? |
Posted at 23/5/2023 14:02 by bloomberg2 ETX get on it while it's under the radar |
Posted at 25/10/2021 13:44 by ali47fish etx reports tomorrow and and a presentation- anyone knows hoot access the latter please |
Posted at 18/10/2021 18:51 by 1347 Not aware ETX are running any clinical trails themselves are they, do you have a CT reference? Of course those using their platform(s) may be but not sure what may be imminent on that front. |
Posted at 02/8/2021 07:41 by dplewis1 Someone fancies a few ETX shares this morning... |
Posted at 04/6/2020 17:14 by paulcon1 DP.....I agree but my initial reason for investing was the share price was at 2p, the MKt Value was 6-7 million (approx) and investors were taking advantage of Mr Woodford's misery... At 21.75p (week back) I thought ETX share price was in unchartered waters and needed a contract to justify the share price . Other posters disagreed... It is very difficult to place a price on potential and Intellectual Property.. That said, ETX, look to have great technology that could have game-changing possibilities, have a strong team and some wealthy investors seem to be very keen to hoover up shares. The more I read (and partially understand) the more impressed I am with their work and vision. I bought some shares at 17.25p today... The joys of investing!! GLA and IMHO |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
